BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 24354513)

  • 1. Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
    An X; Xu G; Yang L; Wang Y; Li Y; McHepange UO; Shen G; Tu Y; Tao J
    J Dermatol; 2014 Jan; 41(1):76-83. PubMed ID: 24354513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.
    Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X
    Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.
    Jokilehto T; Rantanen K; Luukkaa M; Heikkinen P; Grenman R; Minn H; Kronqvist P; Jaakkola PM
    Clin Cancer Res; 2006 Feb; 12(4):1080-7. PubMed ID: 16489060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of ezrin in epithelial skin tumors: cytoplasmic ezrin immunoreactivity in squamous cell carcinoma.
    Park HR; Min SK; Min K; Jun SY; Seo J; Kim KH; Choi J
    Int J Dermatol; 2010 Jan; 49(1):48-52. PubMed ID: 20465611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway.
    Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R
    Skelet Muscle; 2016; 6():5. PubMed ID: 26949511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
    Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
    Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of hypoxia-inducible factor-1alpha and vessel endothelial growth factor in esophageal squamous cell carcinoma and clinico-pathological significance thereof].
    Yu ZT; Zhao HF; Shang XB
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(35):2465-9. PubMed ID: 19080625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR10 and CCL27 are overexpressed in cutaneous squamous cell carcinoma.
    Kai H; Kadono T; Kakinuma T; Tomita M; Ohmatsu H; Asano Y; Tada Y; Sugaya M; Sato S
    Pathol Res Pract; 2011 Jan; 207(1):43-8. PubMed ID: 21144674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of promyelocytic leukaemia protein in Bowen's disease, skin squamous cell carcinoma and basal cell carcinoma].
    Wang Q; Ma H; Wang S; Ma Y; Zou X; Li R
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul; 33(7):1075-7. PubMed ID: 23895857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased activation of the hypoxia-inducible factor pathway in varicose veins.
    Lim CS; Kiriakidis S; Paleolog EM; Davies AH
    J Vasc Surg; 2012 May; 55(5):1427-39. PubMed ID: 22277691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha with progression of keratinocytic neoplasms.
    Lining X; Uchi H; Hayashida S; Tsuji G; Kido M; Nakahara T; Takeuchi S; Takahara M; Moroi Y; Furue M
    J Dermatol Sci; 2009 Nov; 56(2):135-6. PubMed ID: 19660915
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
    Brasanac D; Boricic I; Todorovic V; Tomanovic N; Radojevic S
    Br J Dermatol; 2005 Dec; 153(6):1166-75. PubMed ID: 16307653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene.
    Wu S; Nishiyama N; Kano MR; Morishita Y; Miyazono K; Itaka K; Chung UI; Kataoka K
    Mol Ther; 2008 Jul; 16(7):1227-34. PubMed ID: 18500250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible factors in the first trimester human lung.
    Groenman F; Rutter M; Caniggia I; Tibboel D; Post M
    J Histochem Cytochem; 2007 Apr; 55(4):355-63. PubMed ID: 17189520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation.
    Takeda K; Fong GH
    Hypertension; 2007 Jan; 49(1):178-84. PubMed ID: 17101841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RUNX3 inhibits hypoxia-inducible factor-1α protein stability by interacting with prolyl hydroxylases in gastric cancer cells.
    Lee SH; Bae SC; Kim KW; Lee YM
    Oncogene; 2014 Mar; 33(11):1458-67. PubMed ID: 23542169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of L-type amino acid transporter 1 in various skin lesions.
    Hirano K; Uno K; Kuwabara H; Kojima K; Ohno S; Sakurai H; Kamma H; Kurata A
    Pathol Res Pract; 2014 Oct; 210(10):634-9. PubMed ID: 24939142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipophilic modification enhances anti-colitic properties of rosmarinic acid by potentiating its HIF-prolyl hydroxylases inhibitory activity.
    Jeong S; Park H; Hong S; Yum S; Kim W; Jung Y
    Eur J Pharmacol; 2015 Jan; 747():114-22. PubMed ID: 25483211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density lipoproteins augment hypoxia-induced angiogenesis via regulation of post-translational modulation of hypoxia-inducible factor 1α.
    Tan JT; Prosser HC; Vanags LZ; Monger SA; Ng MK; Bursill CA
    FASEB J; 2014 Jan; 28(1):206-17. PubMed ID: 24022405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of
    Li XY; Wu CH; Yan YJ; Wang DH; Wang MJ; Hou ZW
    Zhongguo Zhen Jiu; 2022 Nov; 42(11):1278-84. PubMed ID: 36397226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.